Phase Holographic Imaging logotype

Investor Relations

Welcome to the Investor Relations for Phase Holographic Imaging (PHI)

What’s New

Press Releases

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
12345…134

News featuring PHI

Biostock PHI CEO comments on the approved US listing

BioStock: PHI’s CEO comments on the approved US listing

PHI has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
12345…30

About PHI

Phase Holographic Imaging (PHI) develops and markets its non-invasive time-lapse imaging instruments. The company’s current HoloMonitor® products are globally used for long-term quantitative analysis of living cell cultures, particularly in preclinical research.

Now, PHI is actively focusing on business development. With unique solutions focused on Quantitative Phase Imaging (QPI) — a technology that brings a novel, cell-friendly approach to critical cell quality evaluation, PHI is expanding into the fast-growing regenerative medicine field.

PHI envisions transforming live cell analysis and establishing its QPI technology as a standard for cell quality control, making our future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.

Learn more about PHI
Key Figures
Why invest in PHI?

July 2024 Interview with PHI AB — Step inside our headquarters and meet the team!

Finwire Media interviewed us about our current business and future outlook in regenerative medicine. How are we shaping the future of scientific research and cell therapy quality control with our innovative live cell analysis technology? How are we positioned to reach profitability, and why do investors take a closer look at PHI?

Investor Information

report banner investor relations

All Press Releases

Here you can read all PHI press releases.

Read Press Releases
A fluorescence equipped HoloMonitor system operating inside a cell incubator at Novo Nordisk A/S

Company News

Here you see PHI featured in news and CEO commentaries.

See Company News
graph banner

Reports & Documents

Here you find PHI’s interim and annual reports, as well as view general meeting and emission documents.

Find Reports & Documents
question banner investor relations phase holographic imaging

Investor Q&A

Here you can browse the frequently asked investor questions and quickly find your answers.

Browse Investor Q&A

Any questions? Please get in touch with our CEO,
Anders Månsson, at: ir@phiab.com

Investor Calendar

Extraordinary General Meeting

December 2, 2024

Interim Report 2 2024/25

December 19, 2024

Stock Information

The PHI stock is listed on the Spotlight Stock Market,
a Multilateral Trading Facility (MTF).

PHI on Swedish Spotlight Market (PHI)

Since August 15th, 2024, PHI has also been dual-listed on the US-based OTCQB Venture Market.

PHI on US-OTCQB Market (OTCQB:PHIXF)

Subscribe to the latest PHI news from BioStock, Kalqyl and Cision to stay informed.
You are welcome to follow PHI on social media, where we keep in touch with our global HoloMonitor community.

Thank you to our investor community for sharing our vision, and believing in the company and the impact our products and technology have on advancing research within life science and the future of medicine.